Phibro Animal Health Corporation
General ticker "PAHC" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $1.6B (TTM average)
Phibro Animal Health Corporation does not follow the US Stock Market performance with the rate: -15.6%.
Estimated limits based on current volatility of 2.6%: low 37.53$, high 39.54$
Factors to consider:
- Company pays dividends (quarterly): last record date 2026-06-03, amount 0.12$ (Y1.20%)
- Total employees count: 2475 (+27.6%) as of 2025
- US accounted for 57.5% of revenue in the fiscal year ended 2024-06-30
- Top business risk factors: Disease outbreaks, Customer demand reduction, Rising input costs, Manufacturing disruptions, Cybersecurity threats
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2026-06-30 to 2028-06-29
- 2026-06-30 to 2027-06-30 estimated range: [22.24$, 38.07$]
- 2027-06-30 to 2028-06-29 estimated range: [21.26$, 36.50$]
Financial Metrics affecting the PAHC estimates:
- Positive: with PPE of 9.8 at the end of fiscal year the price was neutral
- Positive: 7.80 < Operating profit margin, % of 13.07
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: 18.97 < Shareholder equity ratio, % of 25.68 <= 42.26
- Negative: Investing cash flow per share per price, % of -5.61 <= -4.49
- Negative: Interest expense per share per price, % of 3.74 > 3.34
- Positive: 0.28 < Operating cash flow per share per price, % of 5.41
- Negative: 0 < Inventory ratio change, % of 0.52
Short-term PAHC quotes
Long-term PAHC plot with estimates
Financial data
| YTD | 2024-06-30 | 2025-06-30 | 2026-06-30 |
|---|---|---|---|
| Operating Revenue | $1,017.68MM | $1,296.21MM | $1,518.09MM |
| Operating Expenses | $964.36MM | $1,185.75MM | $1,319.66MM |
| Operating Income | $53.31MM | $110.47MM | $198.44MM |
| Non-Operating Income | $-42.40MM | $-42.47MM | $-61.09MM |
| Interest Expense | $18.54MM | $34.60MM | $47.60MM |
| Income(Loss) | $10.92MM | $67.99MM | $137.35MM |
| Taxes | $8.50MM | $19.73MM | $37.63MM |
| Net Income(Loss)* | $2.42MM | $48.26MM | $199.44MM |
| Stockholders Equity | $256.64MM | $285.68MM | $385.48MM |
| Inventory | $265.91MM | $444.43MM | $534.88MM |
| Assets | $982.18MM | $1,360.90MM | $1,501.24MM |
| Operating Cash Flow | $87.59MM | $80.12MM | $68.95MM |
| Capital expenditure | $41.24MM | $38.29MM | $59.09MM |
| Investing Cash Flow | $-48.19MM | $-288.69MM | $-71.45MM |
| Financing Cash Flow | $-6.77MM | $207.13MM | $-6.56MM |
| Earnings Per Share** | $0.06 | $1.19 | $4.91 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.